Clinuvel Pharmaceuticals AI Stock Analysis
Clinuvel Pharmaceuticals (CLVLF) AI Stock Analysis
Clinuvel Pharmaceuticals
(Other OTC:CLVLF)
No summary available
Clinuvel Pharmaceuticals (CLVLF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $249.91M
- Dividend Yield
- 0.75%
- Average Volume (3M)
- 4,097
- Price to Earnings (P/E)
- 10.6
- Beta (1Y)
- 0.06
- Revenue Growth
- 5.04%
- EPS Growth
- -0.47%
- Country
- US
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Company Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the...
Clinuvel Pharmaceuticals Earnings Call Summary
The call was predominantly positive, emphasizing a 10th consecutive year of profitability, revenue above AUD 100 million, strong margins, increasing cash reserves, a debt-free balance sheet, continued R&D investment, and multiple strategic and clinical catalysts. The main challenges were moderated U.S. sales due to competitor trial programs, currency translation effects, a long vitiligo development timeline, continued FDA engagement requirements, and PhotoCosmetics not yet being ready for launch.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management said that, on average, over the next 5 years, expenditure will be about AUD 55 million each year; it is guiding the business by an 83% gross profit margin and 36% net profit margin, and expects EPP growth to be “probably not double digit, but single digit.” The CUV105 top-line results and start of the CUV107 study are both expected in Q4, with CUV107 planned to run for approximately 2 years from recruitment in November 2026 and readout expected in 2029. The target is 190 trained accredited centers by 2027, while vitiligo treatment is assessed at 7 and 12 implants per patient as a one-off treatment, with 1 to 2 injections per year as maintenance; NEURACTHEL is planned to be filed with the EMA in the second half of this calendar year, followed by the FDA, with an average turnaround time of 12 to 16 months after filing a dossier.
Clinuvel Pharmaceuticals Peers Comparison
Overall Rating
AU:BIO69Neutral
AU:PYC50Neutral
AU:ACR47Neutral
AU:SPL44Neutral
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 69Neutral | AUD 79.84M | 20.19 | 46.74% | ― | 29.68% | 1520.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | AUD 1.61B | -27.33 | -10.31% | ― | ― | 39.63% | |
| 47Neutral | AUD 6.12M | -7.14 | -45.29% | ― | 290.25% | 92.05% | |
| 44Neutral | AUD 200.41M | -23.98 | -42.35% | ― | 145.32% | 25.75% | |
| 38Underperform | AUD 27.63M | -0.28 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLVLF | Clinuvel Pharmaceuticals Limited | 4.71 | -2.40 | -33.69% | |
| AU:ACR | Acrux Limited | 0.01 | -0.00 | -33.33% | |
| AU:SPL | Starpharma Holdings Limited | 0.42 | 0.04 | 10.82% | |
| AU:PYC | PYC Therapeutics Limited | 1.65 | 0.27 | 19.90% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.11 | -91.30% | |
| AU:BIO | Biome Australia Ltd | 0.32 | -0.07 | -17.95% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
